Purchase this article with an account.
E. Donnenfeld, K. Solomon, R. Chu; The Effect of a Topical NSAID, Ketorolac Tromethamine 0.4%, on Quality of Vision With a Multifocal IOL . Invest. Ophthalmol. Vis. Sci. 2006;47(13):617.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of a topical NSAID on quality of vision and macula thickening with a multifocal IOL
A multicenter, randomized, masked prospective clinical trial to evaluate the effect of ketorolac tromethamine 0.4% four times a day for 3 days preop and 3 weeks postop versus placebo on the quality of vision in 50 patients bilaterally implanted with the ReSTOR IOL. UCVA, BCVA, mesopic and photopic contrast sensitivity under high contrast and low contrast illumination were measured unilaterally at 2 weeks and 3 months following second eye implantation. In addition patients will perform a life style and life style vision questionnaire at 3 months.
At 2 weeks following the second eye implantation, the patients who received the ketorolac tromethamine 0.4% had statistically significant improved UCVA, BCVA, and contrast sensitivity as compared to patients receiving placebo. Life style and life style vision questionnaire at 3 months supported improved patient satisfaction with their multifocal IOL when they received topical ketorolac tromethamine 0.4% versus placebo.
The preoperative and postoperative use of ketorolac tromethamine 0.4% significantly improved visual outcomes in patients bilaterally implanted with the ReSTOR multifocal IOL.
This PDF is available to Subscribers Only